Abstract: This invention provides a therapeutic agent capable of specifically forming a complex with human immunodeficiency virus envelope glycoprotein which comprises a polypeptide. In one embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +185 fused to the amino acid sequence from about +353 to about +371. In another embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +106 fused to the amino acid sequence from about +353 to about +371. In yet a further embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +185.
Type:
Application
Filed:
June 25, 2001
Publication date:
January 22, 2004
Applicants:
The Trustees of Columbia University, SmithKline Beckman Corporation
Inventors:
Paul J. Maddon, Richard Axel, Raymond W. Sweet, James Arthos
Abstract: This invention relates to a process for producing a heterologous polypeptide in Streptomyces which involves transforming a Streptomyces organism with a recombinant DNA molecule comprising an LEP-10 of LTl sequence selected from the group consisting of a sequence encoding a gene expression unit, a promoter sequence or an export control encoding sequence each operatively linked to a heterologous coding sequence and then culturing the transformed Streptomyces such that the heterologous polypeptide is expressed.
Type:
Grant
Filed:
December 3, 1993
Date of Patent:
March 12, 1996
Assignee:
SmithKline Beckman Corporation
Inventors:
Thomas R. Berka, James A. Fornwald, Joselina G. Gorniak, Martin Rosenberg, James E. Strickler, Dean P. Taylor
Abstract: This invention provides a therapeutic agent capable of specifically forming a complex with human immunodeficiency virus envelope glycoprotein which comprises a polypeptide. In one embodiment of the invention, the amino acid sequence of the polypeptide has the amino acid sequence shown in FIG. 6 from about +1 to about +185 fused to the amino acid sequence from about +353 to about +371. In another embodiment of the invention, the amino acid sequence of the polypeptide has the amino acid sequence shown in FIG. 6 from about +1 to about +106 fused to the amino acid sequence from about +353 to about +371. In yet a further embodiment of the invention, the amino acid sequence of the polypeptide has the amino acid sequence shown in FIG. 6 from about +1 to about +185.This invention also provides a method for treating a subject infected with a human immunodeficiency virus.
Type:
Grant
Filed:
February 5, 1992
Date of Patent:
June 6, 1995
Assignees:
The Trustees of Columbia University in the City of New York, SmithKline Beckman Corporation
Inventors:
Paul J. Maddon, Richard Axel, Raymond W. Sweet, James Arthos
Abstract: An analog of porcine growth hormone, is disclosed which retains the diabetogenic, insulin-sparing and lipolytic properties of porcine growth hormone while being capable of improving growth in mammals.
Abstract: This invention provides a therapeutic agent capable of specifically forming a complex with human immunodeficiency virus envelope glycoprotein which comprises a polypeptide. In one embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +185 fused to the amino acid sequence from about +353 to about +371. In another embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +106 fused to the amino acid sequence from about +353 to about +371. In yet a further embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +185.This invention also provides a method for treating a subject infected with a human immunodeficiency virus.
Type:
Grant
Filed:
February 24, 1988
Date of Patent:
May 5, 1992
Assignees:
The Trustees of Columbia University in the City of New York, Smithkline Beckman Corporation
Inventors:
Paul J. Maddon, Richard Axel, Raymond W. Sweet, James Arthos
Abstract: Pharmaceutical compositions and a method for inhibiting the growth of tumor cells by administering a tumor cell growth-inhibiting amount of a bis[bis (diphenylphosphino)hydrocarbon]-, bis[bis(diethylphsophino) hydrocarbon]-, bis[bis(diphenylphosphine-deithylphosphino) hydrocarbon]gold(I), silver(I) or copper(I) complex or a tris[bis(diphenylphosphino)ethane] dicopper(I) complex to an animal afflicted with said tumor cells.
Type:
Grant
Filed:
June 11, 1986
Date of Patent:
August 6, 1991
Assignee:
SmithKline Beckman Corporation
Inventors:
Susan J. Berners-Price, Randall K. Johnson, Christopher K. Mirabelli, Peter J. Sadler
Abstract: 6-Aryl-2,3-dihydroimidazo[2,1-b]thiazoles and corresponding thiazines act as nucleophiles, either directly or in the form of Grignard reagents, with N-acylpyridinium salts to produce new 6-aryl-5-(N-acyl-1,4-dihydro-4-pyridyl)-2,3-dihydroimidazo-[2,1-b]thiazole s and corresponding thiazines. These are oxidized to give the corresponding pyridyl-substituted imidazo[2,1-b]thiazoles and thiazines, which are active as inhibitors of the 5-lipoxygenase pathway of arachidonic acid metabolism.
Type:
Grant
Filed:
November 3, 1988
Date of Patent:
April 16, 1991
Assignee:
SmithKline Beckman Corporation
Inventors:
Paul E. Bender, Ivan Lantos, Michael A. McGuire, Lendon N. Pridgen, Herbert B. Winicov
Abstract: Invented are phosphinic acid substituted analogues of steroidal synthetic compounds, pharamaceutical compositions containing these compounds, and methods of using these compounds to inhibit steroid 5-.alpha.-reductase, including using these compounds to reduce or maintain prostate size.
Type:
Grant
Filed:
December 23, 1988
Date of Patent:
June 26, 1990
Assignee:
SmithKline Beckman Corporation
Inventors:
Dennis A. Holt, Mark A. Levy, Brian W. Metcalf
Abstract: Potent dopamine-.beta.-hydroxylase inhibitors having the Formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals.
Type:
Grant
Filed:
December 29, 1987
Date of Patent:
June 19, 1990
Assignee:
SmithKline Beckman Corporation
Inventors:
Lawrence I. Kruse, Stephen T. Ross, Eliot H. Ohlstein
Abstract: Potent dopamine-.beta.-hydroxylase inhibitors having the Formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.
Type:
Grant
Filed:
September 15, 1989
Date of Patent:
March 27, 1990
Assignee:
SmithKline Beckman Corporation
Inventors:
Lawrence I. Kruse, Stephen T. Ross, Eliot H. Ohlstein
Abstract: Invented are substituted acrylate analogues of steroidal synthetic compounds, pharmaceutical compositions containing the compounds, and methods of using these compounds to inhibit steroid 5-.alpha.-reductase. Also invented are intermediates used in preparing these compounds.
Type:
Grant
Filed:
December 1, 1987
Date of Patent:
March 20, 1990
Assignee:
SmithKline Beckman Corporation
Inventors:
Dennis A. Holt, Mark A. Levy, Brian W. Metcalf
Abstract: New compounds which have potent V.sub.2 -vasopressin antagonistic activity are prepared by a 1,6-cyclization using peptide bond formation. The structures of the compounds are characterized by a Pas.sup.1,6 or Tas.sup.1,6 cyclized unit. Also a chiral synthesis of the optically pure Pas intermediates is described.
Type:
Grant
Filed:
May 9, 1988
Date of Patent:
March 13, 1990
Assignee:
SmithKline Beckman Corporation
Inventors:
James F. Callahan, William F. Huffman, Kenneth A. Newlander, Nelson C. F. Yim
Abstract: 2-pyridyl and 4-pyridyl phosphine gold compounds of the formula: ##STR1## and 2-pyridyl phosphine gold compounds of the formula: ##STR2## and pharmaceutical compositions containing an effective, tumor cell growth-inhibiting amount of such a compound.
Abstract: Invented are 4-aza-5-alpha-8(14)-17 substituted-androsten-3-ones having an 8(14), 7(8), or 16(17) double bond, optionally also having a 1(2) double bond, pharmaceutical compositions containing the compounds, and methods of using these compounds to inhibit steroid 5-alpha-reductase.
Type:
Grant
Filed:
July 28, 1987
Date of Patent:
December 19, 1989
Assignee:
SmithKline Beckman Corporation
Inventors:
Dennis A. Holt, Mark A. Levy, Brian W. Metcalf
Abstract: Invented are phosphonic acid substituted analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds to inhibit steroid 5-.alpha.-reductase, including using these compounds to reduce or maintain prostate size. Also invented are intermediates used in preparing these compounds.
Type:
Grant
Filed:
December 23, 1988
Date of Patent:
November 21, 1989
Assignee:
SmithKline Beckman Corporation
Inventors:
Dennis A. Holt, Mark A. Levy, Brian W. Metcalf
Abstract: Carboxamide derivatives of glcopeptide antibiotics and their salts are useful for treating or preventing infection in an animal by gram-positive bacteria and also increase feed-utilization efficiency, promote growth in domestic animals and increase propionate production in lactating ruminants.
Abstract: Potent dopamine-.beta.-hydroxylase inhibitors having the Formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mannals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.
Type:
Grant
Filed:
December 29, 1987
Date of Patent:
November 21, 1989
Assignee:
SmithKline Beckman Corporation
Inventors:
Lawrence I. Kruse, Stephen T. Ross, Eliot H. Ohlstein